In Europe, twenty million people live with immune-mediated diseases such as psoriasis and psoriatic arthritis, which, although distinct, share common roots: an imbalance in the immune system that leads to chronic inflammation and a significant impact on patients' quality of life. These conditions not only limit the ability to carry out daily activities but are often accompanied by comorbidities, including depression, making daily life extremely difficult for those who suffer from them. Fortunately, the advent of innovative therapies aimed at specific immunological targets is opening new paths to clinical remission or, at the very least, effective management of the disease. One of these revolutionary therapies is Guselkumab, developed by Janssen, the first fully human monoclonal antibody that selectively targets interleukin 23, a key factor in the inflammatory process underlying these diseases. This treatment, approved in Europe, the United States, Canada, Japan and several other countries, has demonstrated efficacy in the treatment of adult patients with moderate to severe plaque psoriasis, offering new hope to those seeking effective solutions to manage their condition. In Italy, the national health system reimburses the treatment for plaque psoriasis, marking an important step forward in the treatment of this disease. The effectiveness of these targeted therapies is not limited to the treatment of symptoms but extends its benefits to a significant improvement in the quality of life of patients, also addressing psychological issues such as anxiety and depression that often accompany these diseases. The therapeutic approach offered by treatments such as Guselkumab represents a turning point in the fight against psoriasis and psoriatic arthritis, diseases that until now have been difficult to manage. Thanks to scientific research and pharmaceutical innovation, today we can look with greater optimism at the lives of millions of people affected by these conditions, offering them not only effective management of symptoms but also an improved quality of life. These developments in the field of medicine demonstrate the potential of targeted therapies and the importance of investing in research and development to fight immune-mediated diseases. Interviews with: Ketty Peris President SIDeMaST; Ennio Lubrano Full Professor of Rheumatology at the University of Molise; Carlo Francesco Selmi Head of Rheumatology and Clinical Immunology IRCCS Humanitas Rozzano (MI); Giovanna Malara Director of the Dermatology Department of the Grande Ospedale Metropolitano of Reggio Calabria. #guselkumab #psoriasis #psoriatic arthritis #innovation 🛎️ Don't miss our videos, subscribe to the channel and activate the bell to receive all the notifications about new content! 🛎️ ********************* 🔥 Follow us! WebTV: http://PianetaSalute.TV Magazine: https://www.PianetaSalute.online Instagram: / pianetasalute2.0 Twitter: / pianetasalute Facebook: / pianetasalute Linkedin: / pianeta-salute-agenzia-di-stampa-tv WhatsApp: https://whatsapp.com/channel/0029VaDP... Telegram: https://t.me/pianetasalute Digital terrestrial: National channel 221 Pianeta Salute TV 00:00 Introduction to immune-mediated diseases 00:41 Targeted therapies for psoriasis and psoriatic arthritis 01:15 Approval and reimbursement of the drug Guselkumab 01:48 Characteristics of psoriatic arthritis 03:27 The role of subcutaneous targeted therapies 04:18 Efficacy and safety of treatment with Guselkumab 05:57 Psoriasis as a systemic disease 08:36 Guselkumab: An antibody for Psoriasis and Arthritis 09:19 Therapeutic Innovations and Reimbursement 10:02 Mechanisms Underlying Psoriatic Arthritis and Psoriasis 10:40 Blockade of Interleukin 23 11:18 Psoriasis as a Systemic Disease 12:05 Spread and Manifestations of Psoriasis 14:22 Psoriatic Arthritis: Genetic Predisposition and Environmental Factors 16:37 Role of Interleukin 23 in Psoriasis and Other Autoimmune Diseases 17:16 Importance of Inhibiting Interleukin 23 Activity 17:54 Comparison between Interleukin 23 Inhibitors and Cortisone 18:31 New Molecules on the Market: V6 Command and Immunoglobulin Lambda G1 19:15 Clinical Studies to Verify the Efficacy and Safety of the Drug 20:00 Positive results of patients treated with the drug 20:43 Evaluation of the drug's efficacy through the calculation of PASI 21:27 Improvement of the quality of life of patients with the reduction of PASI